bioMérieux and the University of Pittsburgh Form Research Partnership
A strategic R&D partnership between bioMérieux and the University of Pittsburgh (Pitt) has been launched, paving the way for many innovative and collaborative research projects.
Aligned with its geographical expansion and business growth, bioMérieux signed in October 2023, a new Research Master Agreement with the University of Pittsburgh (Pennsylvania, USA). This 3-year contract offers a great opportunity to pioneer the development of innovative diagnostic solutions within the field of infectious diseases.
The inaugural collaboration project is related to sequencing and engages the bioMérieux Analytical and Sequencing team alongside Pitt’s Division of Clinical Microbiology and Division of Infectious Diseases.
“bioMérieux is very proud to start this strategic R&D collaboration with the University of Pittsburgh, especially as it creates a privileged relationship with clinicians in clinical labs, the Infectious Diseases department, and the ICU department. These interactions are indeed invaluable for shaping future innovative diagnostic solutions for infectious diseases, ultimately contributing to improving patient health”, said François Lacoste, Executive Vice President, Research & Development at bioMérieux. Indeed, the University of Pittsburgh is a renowned research institution recognized as one of the most innovative universities in the world and is associated with the University of Pittsburgh Medical Center (UPMC), one of the leading academic health care systems in the U.S.
This partnership fully meets bioMérieux innovation strategy, which aims to build strategic partnerships worldwide, and aligns with Pitt’s mission of fostering translational research through industry collaborations.
“bioMérieux is a worldwide leader in in-vitro diagnostics and testing solutions that address the health challenges posed by infectious diseases. Through this strategic collaboration across multiple university labs and departments, University of Pittsburgh researchers and clinicians are excited to work with bioMérieux scientists to confront these challenges and improve patient care by developing innovative diagnostic approaches for numerous infectious diseases,” said Joseph Havrilla, Associate Vice Chancellor for Innovation and Entrepreneurship at Pitt.
University of Pittsburgh